High liposomal doxorubicin tumour tissue distribution, as determined by radiopharmaceutical labelling with 99mTc-LD, is associated with the response and survival of patients with unresectable pleural mesothelioma treated with a combination of liposomal doxorubicin and cisplatin

Cancer Chemotherapy and Pharmacology

Volumn 74, Issue 1, 2014, Pages 211-215

  Arrieta, Oscar ^a   Medina, Luis Alberto ^a,b   Estrada Lobato, Enrique ^a   Ramírez Tirado, Laura Alejandra ^a   Mendoza García, Víctor Osvaldo ^a   De La Garza Salazar, Jaime ^a  

^a INSTITUTO NACIONAL DE CANCEROLOGÍA   (Mexico)

^b UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

Author keywords

Chemotherapy; Mesothelioma; Response rate; Uptake

Indexed keywords

APREPITANT; CISPLATIN; DEXAMETHASONE; DOXORUBICIN; ONDANSETRON; TECHNETIUM 99M;

ADULT; ADVANCED CANCER; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CLINICAL ARTICLE; DRUG DISTRIBUTION; DRUG TUMOR LEVEL; DRUG UPTAKE; FEMALE; FOLLOW UP; HISTOLOGY; HUMAN; INOPERABLE CANCER; ISOTOPE LABELING; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SMOKING; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOLOGICAL MARKERS; CISPLATIN; DOXORUBICIN; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIPOSOMES; MALE; MESOTHELIOMA; MIDDLE AGED; NEOPLASM STAGING; PHARMACEUTICAL VEHICLES; PLEURAL NEOPLASMS; PROGNOSIS; RADIOPHARMACEUTICALS; SURVIVAL ANALYSIS; TECHNETIUM; TISSUE DISTRIBUTION; TUMOR BURDEN;

EID: 84903818206     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-014-2477-x     Document Type: Article

References (20)

1. Aguilar-Madrid G, Robles-Pérez E, Juárez-Pérez CA, Alvarado-Cabrero I, Rico-Méndez FG, Javier KG (2010) Case-control study of pleural mesothelioma in workers with social security in Mexico. Am J Ind Med 53(3):241-251. doi:10.1002/ajim.20780
2. Ardizzoni A, Rosso R, Salvati F, Fusco V, Cinquegrana A, De Palma M, Serrano J, Pennucci MC, Soresi E, Crippa M, Gulisano M, Castagneto B, Scagliotti G, Rinaldi M (1991) Activity of doxorubicin and cisplatin combination chemotherapy in patients with diffuse malignant pleural mesothelioma. An Italian Lung Cancer Task Force (FONICAP) Phase II study. Cancer 67(12):2984-2987
3. Arrieta Ó, Medina LA, Estrada-Lobato E, Hernández-Pedro N, Villanueva-Rodríguez G, Martínez-Barrera L, Macedo EO, López-Rodríguez V, Motola-Kuba D, Corona-Cruz JF (2012) First-line chemotherapy with liposomal doxorubicin plus cisplatin for patients with advanced malignant pleural mesothelioma: phase II trial. Br J Cancer 106(6):1027-1032. doi:10.1038/bjc.2012.44
4. Baas P, van Meerbeeck J, Groen H, Schouwink H, Burgers S, Daamen S, Giaccone G (2000) Caelyx™ in malignant mesothelioma: a phase II EORTC study. Ann Oncol 11(6):697-700
5. Bénard F, Sterman D, Smith RJ, Kaiser LR, Albelda SM, Alavi A (1998) Metabolic imaging of malignant pleural mesothelioma with fluorodeoxyglucose positron emission tomography. Chest 114(3):713-722 (Pubitemid 28433730)
6. Head HW, Dodd GD 3rd, Bao A, Soundararajan A, Garcia-Rojas X, Prihoda TJ, McManus LM, Goins BA, Santoyo CA, Phillips WT (2010) Combination radiofrequency ablation and intravenous radiolabeled liposomal doxorubicin: imaging and quantification of increased drug delivery to tumors. Radiology 255(2):405-414. doi:10.1148/radiol.10090714
7. Health and Safety Executive (2013) Mesothelioma in Great Britain 2013. Mesothelioma mortality in Great Britain 1968-2011. Health and Safety Executive, UK
8. Henss H, Fiebig H, Schildge J, Arnold H, Hasse J (1988) Phase-II study with the combination of cisplatin and doxorubicin in advanced malignant mesothelioma of the pleura. Onkologie 11(3):118-120
9. Ji S, Zheng Y, Shao G, Zhou Y, Liu S (2013) Integrin αvβ3- targeted radiotracer (99m)Tc-3P-RGD2 useful for noninvasive monitoring of breast tumor response to antiangiogenic linifanib therapy but not anti-integrin αvβ3 RGD2 therapy. Theranostics 3(11):816-830. doi:10.7150/thno.6989
10. Kao SC, Lee K, Klebe S, Henderson D, McCaughan B, Vardy J, Clarke S, van Zandwijk N (2013) Excision repair cross complementation group 1 and thymidylate synthase expression in mesothelioma patients. Clin Lung Cancer 14(2):164-171. doi:10.1016/j.cllc.2012.09.003
11. Kim ES, Lee JJ, He G, Chow CW, Fujimoto J, Kalhor N, Swisher SG, Wistuba II, Stewart DJ, Siddik ZH (2012) Tissue platinum concentration and tumor response in non-small-cell lung cancer. J Clin Oncol 30(27):3345-3352. doi:10.1200/JCO.2011.40.8120
12. Lee CW, Murray N, Anderson H, Rao SC, Bishop W (2009) Outcomes with first-line platinum-based combination chemotherapy for malignant pleural mesothelioma: a review of practice in British Columbia. Lung Cancer 64(3):308-313. doi:10.1016/j.lungcan.2008.09.008
13. Lustgarten DE, Deshpande C, Aggarwal C, Wang LC, Saloura V, Vachani A, Wang LP, Litzky L, Feldman M, Creaney J, Nowak AK, Langer C, Inghilleri S, Stella G, Albelda SM (2013) Thymidylate synthase and folyl-polyglutamate synthase are not clinically useful markers of response to pemetrexed in patients with malignant pleural mesothelioma. J Thorac Oncol 8(4):469-477. doi:10.1097/JTO.0b013e318283da3e
14. Arrieta O, López-Macías D, Mendoza-García VO, Bacon-Fonseca L, Muñoz-Montalvo W, Macedo-Pérez EO, Muñiz-Hernández S, Blake-Cerda M, Corona-Cruz JF (2014) A phase II trial of prolonged, continuous infusion of low-dose gemcitabine plus cisplatin in patients with advanced malignant pleural mesothelioma. Cancer Chemother Pharmacol 73(5):975-982. doi:10.1007/s00280-014-2429-5
15. Pinto C, Novello S, Torri V, Ardizzoni A, Betta PG, Bertazzi PA, Casalini GA, Fava C, Fubini B, Magnani C, Mirabelli D, Papotti M, Ricardi U, Rocco G, Pastorino U, Tassi G, Trodella L, Zompatori M, Scagliotti G (2013) Second Italian consensus conference on malignant pleural mesothelioma: state of the art and recommendations. Cancer Treat Rev 39(4):328-339. doi:10.1016/j.ctrv.2012. 11.004
16. Ralli M, Tourkantonis I, Makrilia N, Gkini E, Kotteas E, Gkiozos I, Katirtzoglou N, Syrigos K (2009) Docetaxel plus gemcitabine as first-line treatment in malignant pleural mesothelioma: a single institution phase II study. Anticancer Res 29(8):3441-3444
17. Sharif S, Zahid I, Routledge T, Scarci M (2011) Does positron emission tomography offer prognostic information in malignant pleural mesothelioma? Interact CardioVasc Thorac Surg 12(5):806-811. doi:10.1510/icvts.2010.255901
18. Sørensen JB, Frank H, Palshof T (2008) Cisplatin and vinorelbine first-line chemotherapy in non-resectable malignant pleuralmesothelioma. Br J Cancer 99(1):44-50. doi:10.1038/sj.bjc.6604421 (Pubitemid 351920221)
19. van Meerbeeck JP, Gaafar R, Manegold C, Van Klaveren RJ, Van Marck EA, Vincent M, Legrand C, Bottomley A, Debruyne C, Giaccone G (2005) European Organisation for Research and Treatment of Cancer Lung Cancer Group; National Cancer Institute of Canada Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol 28:6881-6889
20. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, Niyikiza C, Paoletti P (2003) Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21(14):2636-2644 (Pubitemid 46606305)